IMTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Immatics NV (IMTX) is not a strong buy at the moment for a beginner investor with a long-term strategy. Despite positive analyst ratings and price target increases, the lack of significant trading signals, weak financial performance, and neutral sentiment from hedge funds and insiders suggest a cautious approach. The technical indicators are neutral to slightly bullish, but the absence of recent news or strong catalysts makes this stock less compelling for immediate investment.
The MACD is positive but contracting, RSI is neutral at 51.794, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 9.614, with resistance at 10.378 and support at 8.85. However, the stock's candlestick pattern indicates a 60% chance of slight declines in the short term (-0.52% next day, -2.05% next week, -0.98% next month).
and maintain Buy ratings. Biotech sector sentiment appears to be improving, with positive data catalysts and M&A activity.
Financial performance is weak, with a significant revenue drop (-89.74% YoY in Q3 2025). No recent news or major trading activity from insiders, hedge funds, or Congress. Options data shows higher put open interest, indicating bearish sentiment.
In Q3 2025, revenue dropped significantly by -89.74% YoY to $5,187,000. Net income improved to -$50,545,000 (up 489.79% YoY), and EPS increased to -0.42 (up 425% YoY). Gross margin remained at 100%. While there are improvements in net income and EPS, the revenue decline raises concerns about growth sustainability.
Analysts are bullish, with recent price target increases from BofA ($17) and Guggenheim ($19). Both firms maintain Buy ratings, citing positive data catalysts and improving biotech sector sentiment. However, concerns remain about the sustainability of the sector's recovery.
